Synthesis of isotopically labelled [14C]ZT-1, [d3]ZT-1 & (-)-[d3]huperzine A, a new generation of acetylcholinesterase inhibitors
A method has been developed for the synthesis of two isotopically labelled forms of a pro-drug of the acetylcholinesterase inhibitor ()-huperzine A.
These labelled compounds, [14C]ZT-1 (Debio-9902) and [d3]ZT-1, were used in clinical studies to evaluate a potential treatment for Alzheimer’s disease. The pro-drug [14C]ZT-1 was isolated with a radiochemical purity of >98% and a gravimetric specific activity of 129mCi/mg in a seven-step synthesis starting from [U-14C]phenol in 7% yield.
Subsequently, the deuterium labelled target ()-[d3]huperzine A was achieved in six steps with an overall yield of 15% and gave an isotopic distribution of d2 (1.65% huperzine A) and d3 (97.93% huperzine A) with a chemical purity of 98.5%. Condensation of the substrate ()-[d3]huperzine A with 5-chloro-o-vanillin gave the Schiff base [d3]ZT-1 in a chemical yield of 80%. Reduction of the Schiff base gave reduced-[d3]ZT-1, which was converted into the hydrochloride salt with an isotopic distribution of d2 (1.60%) and d3 (98.02%).
Almac API, Chemical Development, Analytical & Solid State Services
Almac Sciences provides integrated services from development to commercial scale of advanced intermediates and Active Pharmaceutical Ingredients (API).
We provide a range of services for small molecules (including highly potent) and peptides. We have a proven track record of saving time and cost through the integration of our services and application of innovative biocatalysis and technology solutions.
We offer a full suite of analytical testing for a range of different product types including small molecules, peptides, biologics, conjugates, potent and controlled substances.
Our vast pool of scientific knowledge can help to overcome the analytical challenges that typically arise during drug development.